PDP1 and pancreatic neoplasm: In contrast to PD-H and H3N-375/1TS, all pancreatic tumor cell lines were resistant to CVA21, except for Capan-2, which showed moderate sensitivity with a cell viability of 59% at MOI 1 after 48 h.